The rotenone-induced rat model of Parkinson's disease: Behavioral and electrophysiological findings

Behavioural Brain Research

Volumn 279, Issue , 2015, Pages 52-61

  Wrangel, Christof von ^a   Schwabe, Kerstin ^a   John, Nadine ^a   Krauss, Joachim K ^a   Alam, Mesbah ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Local field potentials; Mitochondrial complex I; Parkinson's disease; Rotenone; Single unit activity; Subthalamic nucleus

Indexed keywords

ROTENONE; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRIC POTENTIAL; MALE; MOTOR CORTEX; MOTOR DYSFUNCTION; NERVE CELL; NERVE CELL MEMBRANE POTENTIAL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; RAT; ROTAROD TEST; SINGLE UNIT ACTIVITY; SUBTHALAMIC NUCLEUS; ANIMAL; BETA RHYTHM; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; NEOSTRIATUM; PARKINSONISM; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA; VALIDATION STUDY;

ANIMALS; BETA RHYTHM; DISEASE MODELS, ANIMAL; MALE; MOTOR ACTIVITY; MOTOR CORTEX; NEOSTRIATUM; NEURONS; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; ROTAROD PERFORMANCE TEST; ROTENONE; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; TYROSINE 3-MONOOXYGENASE;

EID: 84911435561     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.11.002     Document Type: Article

References (71)

1. Greenamyre J.T., Sherer T.B., Betarbet R., Panov A.V. Complex I and Parkinson's disease. IUBMB Life 2001, 52:135-141. 10.1080/15216540152845939.
2. Abou-Sleiman P.M., Muqit M.M.K., Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006, 7:207-219. 10.1038/nrn1868.
3. Vila M., Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med 2004, 10. Suppl:S58-62. 10.1038/nm1068.
4. Kamel F. Epidemiology Paths from pesticides to Parkinson's. Science 2013, 341:722-723. 10.1126/science.1243619.
5. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 2009, 34:279-290. 10.1016/j.nbd.2009.01.016.A.
6. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003, 179:9-16.
7. Sonia Angeline M., Chaterjee P., Anand K., Ambasta R.K., Kumar P. Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat. Neuroscience 2012, 220:291-301. 10.1016/j.neuroscience.2012.06.021.
8. Ferris C.F., Marella M., Smerkers B., Barchet T.M., Gershman B., Matsuno-Yagi A., et al. A phenotypic model recapitulating the neuropathology of Parkinson's disease. Brain Behav 2013, 3:351-366. 10.1002/brb3.138.
9. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3:1301-1306. 10.1038/81834.
10. Alam M., Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 2002, 136:317-324.
11. Shimohama S., Sawada H., Kitamura Y., Taniguchi T. Disease model: Parkinson's disease. Trends Mol Med 2003, 9:360-365.
12. Hamani C., Saint-Cyr J.A., Fraser J., Kaplitt M., Lozano A.M. The subthalamic nucleus in the context of movement disorders. Brain 2004, 127:4-20. 10.1093/brain/awh029.
13. Eusebio A., Brown P. Synchronisation in the beta frequency-band--the bad boy of parkinsonism or an innocent bystander?. Exp Neurol 2009, 217:1-3. 10.1016/j.expneurol.2009.02.003.
14. Alam M., Heissler H.E., Schwabe K., Krauss J.K. Deep brain stimulation of the pedunculopontine tegmental nucleus modulates neuronal hyperactivity and enhanced beta oscillatory activity of the subthalamic nucleus in the rat 6-hydroxydopamine model. Exp Neurol 2012, 233:233-242. 10.1016/j.expneurol.2011.10.006.
15. Bergman H., Wichmann T., Karmon B., DeLong M.R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994, 72:507-520.
16. Magill P.J., Bolam J.P., Bevan M.D. Dopamine regulates the impact of the cerebral cortex on the subthalamic nucleus-globus pallidus network. Neuroscience 2001, 106:313-330.
17. Alam M., Schwabe K., Krauss J.K. The pedunculopontine nucleus area: critical evaluation of interspecies differences relevant for its use as a target for deep brain stimulation. Brain 2011, 134:11-23. 10.1093/brain/awq322.
18. Bezard E., Yue Z., Kirik D., Spillantini M.G. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord 2013, 28:61-70. 10.1002/mds.25108.
19. Stocchi F., Olanow C.W. Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Mov Disord 2013, 28:3-7. 10.1002/mds.25337.
20. Perez F.A., Palmiter R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 2005, 102:2174-2179. 10.1073/pnas.0409598102.
21. Levy R., Hutchison W.D., Lozano A.M., Dostrovsky J.O. Synchronized neuronal discharge in the basal ganglia of parkinsonian patients is limited to oscillatory activity. J Neurosci 2002, 22:2855-2861. doi:20026193.
22. Rivlin-Etzion M., Ritov Y., Heimer G., Bergman H., Bar-Gad I. Local shuffling of spike trains boosts the accuracy of spike train spectral analysis. J Neurophysiol 2006, 95:3245-3256. 10.1152/jn.00055.2005.
23. Lesne A., Blanc J-L., Pezard L. Entropy estimation of very short symbolic sequences. Phys Rev E 2009, 79:046208. 10.1103/PhysRevE.79.046208.
24. Chan H-L., Lin M-A., Lee S-T., Tsai Y-T., Chao P-K., Wu T. Complex analysis of neuronal spike trains of deep brain nuclei in patients with Parkinson's disease. Brain Res Bull 2010, 81:534-542. 10.1016/j.brainresbull.2010.01.001.
25. Hu J., Gao J., Principe J.C. Analysis of biomedical signals by the lempel-Ziv complexity: the effect of finite data size. IEEE Trans Biomed Eng 2006, 53:2606-2609. 10.1109/TBME.2006.883825.
26. Lempel A., Ziv J. On the complexity of finite sequences. IEEE Trans Inf Theory 1976, 22:75-81. 10.1109/TIT.1976.1055501.
27. Lindemann C., Alam M., Krauss J.K., Schwabe K. Neuronal activity in the medial associative-limbic and lateral motor part of the rat subthalamic nucleus and the effect of 6-hydroxydopamine-induced lesions of the dorsolateral striatum. J Comp Neurol 2013, 521:3226-3240. 10.1002/cne.23342.
28. Fleming S.M., Zhu C., Fernagut P-O., Mehta A., DiCarlo C.D., Seaman R.L., et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 2004, 187:418-429. 10.1016/j.expneurol.2004.01.023.
29. Alam M., Schmidt W.J. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behav Brain Res 2004, 153:439-446. 10.1016/j.bbr.2003.12.021.
30. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001, 125:109-125.
31. Recchia A., Rota D., Debetto P., Peroni D., Guidolin D., Negro A., et al. Generation of a alpha-synuclein-based rat model of Parkinson's disease. Neurobiol Dis 2008, 30:8-18. 10.1016/j.nbd.2007.11.002.
32. Rozas G., Guerra M.J., Labandeira-García J.L. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 1997, 2:75-84.
33. Swarnkar S., Singh S., Mathur R., Patro I.K., Nath C. A study to correlate rotenone induced biochemical changes and cerebral damage in brain areas with neuromuscular coordination in rats. Toxicology 2010, 272:17-22. 10.1016/j.tox.2010.03.019.
34. Zhou F., Wu J-Y., Sun X-L., Yao H-H., Ding J-H., Hu G. Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 2007, 32:2570-2580. 10.1038/sj.npp.1301381.
35. Bagga P., Chugani A.N., Varadarajan K.S., Patel A.B. In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment. J Neurochem 2013, 127:365-377. 10.1111/jnc.12407.
36. Vernon A.C., Crum W.R., Johansson S.M., Modo M. Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease. PLoS One 2011, 6:e17269. 10.1371/journal.pone.0017269.
37. Olsson M., Nikkhah G., Bentlage C., Björklund a. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995, 15:3863-3875.
38. Grieb B., von Nicolai C., Engler G., Sharott A., Papageorgiou I., Hamel W., et al. Decomposition of abnormal free locomotor behavior in a rat model of Parkinson's disease. Front Syst Neurosci 2013, 7:95. 10.3389/fnsys.2013.00095.
39. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995, 67:631-647.
40. Debeir T., Ginestet L., François C., Laurens S., Martel J-C., Chopin P., et al. Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. Exp Neurol 2005, 193:444-454. 10.1016/j.expneurol.2005.01.007.
41. Roedter A., Winkler C., Samii M., Walter G.F., Brandis A., Nikkhah G. Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways. J Comp Neurol 2001, 432:217-229.
42. Kordower J.H., Olanow C.W., Dodiya H.B., Chu Y., Beach T.G., Adler C.H., et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136:2419-2431. 10.1093/brain/awt192.
43. Féger J. Updating the functional model of the basal ganglia. Trends Neurosci 1997, 20:152-153. 10.1016/S0166-2236(96)01016-8.
44. Albin R.L., Young A.B., Penney J.B. The functional anatomy of disorders of the basal ganglia. Trends Neurosci 1995, 18:63-64.
45. Darbin O., Adams E., Martino A., Naritoku L., Dees D., Naritoku D. Non-linear dynamics in parkinsonism. Front Neurol 2013, 4:211. 10.3389/fneur.2013.00211.
46. Levy R., Dostrovsky J.O., Lang A.E., Sime E., Hutchison W.D., Lozano A.M. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 2001, 86:249-260.
47. Remple M.S., Bradenham C.H., Kao C.C., Charles P.D., Neimat J.S., Konrad P.E. Subthalamic nucleus neuronal firing rate increases with Parkinson's disease progression. Mov Disord 2011, 26:1657-1662. 10.1002/mds.23708.
48. Hollerman J.R., Grace A.A. Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol. Brain Res 1992, 590:291-299.
49. Nambu A., Tokuno H., Takada M. Functional significance of the cortico-subthalamo-pallidal hyperdirect pathway. Neurosci Res 2002, 43:111-117.
50. Hassani O.K., Mouroux M., Féger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996, 72:105-115.
51. Parr-Brownlie L.C., Poloskey S.L., Flanagan K.K., Eisenhofer G., Bergstrom D.A., Walters J.R. Dopamine lesion-induced changes in subthalamic nucleus activity are not associated with alterations in firing rate or pattern in layer V neurons of the anterior cingulate cortex in anesthetized rats. Eur J Neurosci 2007, 26:1925-1939. 10.1111/j. 1460-9568.2007.05814.x.
52. Kirik D., Rosenblad C., Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152:259-277. 10.1006/exnr.1998.6848.
53. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002, 175:303-317. 10.1006/exnr.2002.7891.
54. Ni Z.G., Bouali-Benazzouz R., Gao D.M., Benabid A.L., Benazzouz A. Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats. Brain Res 2001, 899:142-147.
55. Breit S., Bouali-Benazzouz R., Popa R.C., Gasser T., Benabid A.L., Benazzouz A. Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat. Exp Neurol 2007, 205:36-47. 10.1016/j.expneurol.2006.12.016.
56. Steriade M. Corticothalamic resonance, states of vigilance and mentation. Neuroscience 2000, 101:243-276.
57. Gatev P., Darbin O., Wichmann T. Oscillations in the basal ganglia under normal conditions and in movement disorders. Mov Disord 2006, 21:1566-1577. 10.1002/mds.21033.
58. Weinberger M., Hutchison W.D., Dostrovsky J.O. Pathological subthalamic nucleus oscillations in PD: can they be the cause of bradykinesia and akinesia?. Exp Neurol 2009, 219:58-61. 10.1016/j.expneurol.2009.05.014.
59. Brown P., Williams D. Basal ganglia local field potential activity: character and functional significance in the human. Clin Neurophysiol 2005, 116:2510-2519. 10.1016/j.clinph.2005.05.009.
60. Kühn A.A., Kupsch A., Schneider G-H., Brown P. Reduction in subthalamic 8-35Hz oscillatory activity correlates with clinical improvement in Parkinson's disease. Eur J Neurosci 2006, 23:1956-1960. 10.1111/j. 1460-9568.2006.04717.x.
61. Gatev P., Wichmann T. Interactions between cortical rhythms and spiking activity of single basal ganglia neurons in the normal and parkinsonian state. Cereb Cortex 2009, 19:1330-1344. 10.1093/cercor/bhn171.
62. Babiloni C., De Pandis M.F., Vecchio F., Buffo P., Sorpresi F., Frisoni G.B., et al. Cortical sources of resting state electroencephalographic rhythms in Parkinson's disease related dementia and Alzheimer's disease. Clin Neurophysiol 2011, 122:2355-2364. 10.1016/j.clinph.2011.03.029.
63. Pievani M., de Haan W., Wu T., Seeley W.W., Frisoni G.B. Functional network disruption in the degenerative dementias. Lancet Neurol 2011, 10:829-843. 10.1016/S1474-4422(11)70158-2.
64. Bevan M.D., Magill P.J., Terman D., Bolam J.P., Wilson C.J. Move to the rhythm: oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci 2002, 25:525-531.
65. McCairn K.W., Turner R.S. Deep brain stimulation of the globus pallidus internus in the parkinsonian primate: local entrainment and suppression of low-frequency oscillations. J Neurophysiol 2009, 101:1941-1960. 10.1152/jn.91092.2008.
66. Cruz A.V., Mallet N., Magill P.J., Brown P., Averbeck B.B. Effects of dopamine depletion on network entropy in the external globus pallidus. J Neurophysiol 2009, 102:1092-1102. 10.1152/jn.00344.2009.
67. Lafreniere-Roula M., Darbin O., Hutchison W.D., Wichmann T., Lozano A.M., Dostrovsky J.O. Apomorphine reduces subthalamic neuronal entropy in parkinsonian patients. Exp Neurol 2010, 225:455-458. 10.1016/j.expneurol.2010.07.016.
68. Dorval A.D., Russo G.S., Hashimoto T., Xu W., Grill W.M., Vitek J.L. Deep brain stimulation reduces neuronal entropy in the MPTP-primate model of Parkinson's disease. J Neurophysiol 2008, 100:2807-2818. 10.1152/jn.90763.2008.
69. Sanghera M.K., Darbin O., Alam M., Krauss J.K., Friehs G., Jankovic J., et al. Entropy measurements in pallidal neurons in dystonia and Parkinson's disease [abstract]. Mov Disord 2012, 27(Suppl. 1):656.
70. Cicchetti F., Drouin-Ouellet J., Gross R.E. Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?. Trends Pharmacol Sci 2009, 30:475-483. 10.1016/j.tips.2009.06.005.
71. Lapointe N., St-Hilaire M., Martinoli M., Blanchet J., Gould P., Rouillard C., et al. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 2004, 18:717-719. 10.1096/fj.03-0677fje.